InflaRx N V.
InflaRx NV is a small cap stock with a total market cap of 262.91M.
They trade on the NASDAQ and had their IPO 5 years and 7 months
InflaRx NV currently employs 44 people.
News Relating to $IFRX
The Motley Fool
Why InflaRx Stock Skyrocketed This Week
Friday Apr 07 2023 at 10:21
InflaRx stock has soared on news that the company’s Gohibic drug had received Emergency Use Authorization from the FDA. Analysts expect that Gohibic will be priced above $20,000 per treatment course.
Proactive Investors
InflaRx shares pop on FDA emergency use authorization of Covid-19 treatment injection
Wednesday Apr 05 2023 at 15:51
The US Food and Drug Administration (FDA) granted emergency-use authorization (EUA) to InflaRx NV’s monoclonal antibody for the treatment of hospitalized Covid-19 patients, sending the company’s stock soaring. Shares of the German biopharmaceutical company skyrocketed nearly 60% to $6.02 on Wednesday.
Zacks Investment Research
InflaRx (IFRX) Stock Up on FDA’s EUA for COVID-19 Treatment
Wednesday Apr 05 2023 at 12:12
InflaRx (IFRX) shares gain as it receives emergency-use authorization from the FDA for Gohibic (vilobelimab) to treat COVID-19 in terminally-ill patients.
The Motley Fool
Why Shares of InflaRx Are Soaring Wednesday
Wednesday Apr 05 2023 at 11:57
InflaRx is a clinical-stage biotech that focuses on anti-inflammation therapies. Its lead therapy is also seen as a treatment for several skin disorders.
InvestorPlace
InflaRx (IFRX) Stock Pops as FDA Grants Emergency Use Authorization
Wednesday Apr 05 2023 at 10:06
InflaRx (NASDAQ: IFRX ) stock is getting a boost on Wednesday following an update from the FDA concerning its Covid-19 treatment. The big news investors are celebrating today is vilobelimab getting Emergency Use Authorization (EUA) from the FDA.
Seeking Alpha
InflaRx: On Watch For A Buy During Tax Loss Selling Season
Wednesday Dec 14 2022 at 02:34
IFRX has been beaten down much like many other biotech companies. The company has a lead drug which is being considered for EUA in the US and use in the EU for critical covid.
GlobeNewsWire
InflaRx to Present at Upcoming Scientific and Investor Conferences
Friday Sep 09 2022 at 07:30
JENA, Germany, Sept. 09, 2022 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several conferences.
Zacks Investment Research
Here’s Why InflaRx N.V. (IFRX) is a Great Momentum Stock to Buy
Wednesday Aug 17 2022 at 13:33
Does InflaRx N.V. (IFRX) have what it takes to be a top stock pick for momentum investors?
Zacks Investment Research
InflaRx N.V. (IFRX) Upgraded to Buy: What Does It Mean for the Stock?
Thursday Aug 11 2022 at 13:33
InflaRx N.V. (IFRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PennyStocks
Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch
Thursday Jul 28 2022 at 11:30
Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins?
Insider Trading
Data is unavailable for Insider Trading
Debt & Income Analysis
(Original Source: SEC.GOV)
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
$IFRX’s Income Quality of 1.21 is greater than its Industry Group of 0.8 (51.2% greater)
$IFRX’s Income Quality of 1.21 is greater than its Major Industry Group of 0.81 (49.4% greater)
$IFRX’s Income Quality of 1.21 is greater than its Sector of 0.83 (45.8% greater)
(Original Source: SEC.GOV)
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
$IFRX’s Current Ratio of 7.48 is greater than its Industry Group of 4.51 (65.9% greater)
$IFRX’s Current Ratio of 7.48 is greater than its Major Industry Group of 4.13 (81.1% greater)
$IFRX’s Current Ratio of 7.48 is greater than its Sector of 2.48 (201.6% greater)
Value Analysis
(Original Source: SEC.GOV)
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Cannot compare a negative PE Ratio (-9.29 & -1.4)
Cannot compare a negative PE Ratio (-9.29 & -1.22)
Cannot compare a negative PE Ratio (-9.29 & -0.12)
(Original Source: SEC.GOV)
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
$IFRX’s PB Ratio of 2.62 is greater than its Industry Group of 1.39 (88.5% greater)
$IFRX’s PB Ratio of 2.62 is greater than its Major Industry Group of 1.47 (78.2% greater)
$IFRX’s PB Ratio of 2.62 is greater than its Sector of 1.7 (54.1% greater)
Efficiency Analysis
(Original Source: SEC.GOV)
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
$IFRX’s ROE of -0.28 is greater than its Industry Group of -0.47 (40.4% greater)
$IFRX’s ROE of -0.28 is greater than its Major Industry Group of -0.41 (31.7% greater)
Cannot compute a percentage difference when there are zeros in the calculation
(Original Source: SEC.GOV)
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
$IFRX’s ROCE of -0.3 is greater than its Industry Group of -0.43 (30.2% greater)
$IFRX’s ROCE of -0.3 is greater than its Major Industry Group of -0.38 (21.1% greater)
$IFRX’s ROCE of -0.3 is lower than its Sector of 0.01 (-3100.0% lower)